Showing results (21-30 of 1,963) with videos related to

Sort By:
Pageof 197
RMD Open|June 2, 2022
Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDsJames M Gwinnutt, Maud Wieczorek, Javier Rodríguez-Carrio, et al.
RMD Open|June 22, 2022
Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trialByeong-Zu Ghang, Ji Sung Lee, Jihye Choi, et al.
RMD Open|June 23, 2022
Risk of malignancy in rheumatoid arthritis patients initiating biologics: an historical propensity score matched cohort study within the French nationwide healthcare databaseRaphaele Seror, Alexandre Lafourcade, Yann De Rycke, et al.
RMD Open|April 12, 2022
Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trialAtsushi Tanaka, Shigeru Toyoda, Toru Kato, et al.
RMD Open|July 19, 2022
Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COASTJürgen Braun, Uta Kiltz, Atul Deodhar, et al.
RMD Open|July 19, 2022
Cost-effectiveness of motivational counselling and text reminders in patients with rheumatoid arthritis: results based on a randomised clinical trialJan Sørensen, Bente Appel Esbensen, Mette Aadahl, et al.
RMD Open|September 21, 2018
Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitorsPeter Nash, Frank Behrens, Ana-Maria Orbai, et al.
RMD Open|April 17, 2024
Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up periodJessica Polo Y La Borda, Santos Castañeda, Elena Heras-Recuero, et al.
RMD Open|March 1, 2016
Predictive factors of radiological progression after 2 years of remission-steered treatment in early arthritis patients: a post hoc analysis of the IMPROVED studyGülşah Akdemir, Marije K Verheul, Lotte Heimans, et al.
RMD Open|March 1, 2016
Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 studyYoshiya Tanaka, Hisashi Yamanaka, Naoki Ishiguro, et al.
Pageof 197